By Scott M. Grundy
Read Online or Download Cholesterol-Lowering Therapy: Evaluation of Clinical Trial Evidence PDF
Similar clinical medicine books
Potassium ions okay+ ions are important in physiological tactics, fairly with reference to the cardiovascular method. Modulators impression the channels wherein those ions movement and the study into modulator medicinal drugs of those channels is the topic of rapidly-advancing learn. This paintings is meant to be of use as a device for these operating within the pharmaceutical undefined.
Written by way of a workforce of global specialists the ebook presents sensible and specified suggestion for the standard insurance expert chargeable for tracking compliance with felony necessities and permitted criteria of pre-clinical security stories, medical trials and manufacture of gear. It offers a framework for integrating those criteria with different caliber administration platforms.
Polyunsaturated fatty acids are crucial for human mobilephone metabolism. As precursors of a truly huge and intensely flexible kinfolk of signaling compounds they play a key function in intracellular verbal exchange. Eicosanoids represent the most considerable and sought after subfamilies of those fatty acid derivatives that are shaped basically alongside oxidative pathways.
- Statistical aspects of the design and analysis of clinical trials
- Hepatology a clinical textbook 2010 - 2nd edition
- Essentials of Neuroimaging, An Issue of Radiologic Clinics
- Clinical Anatomy 11e
- Clinical Negligence
Additional info for Cholesterol-Lowering Therapy: Evaluation of Clinical Trial Evidence
Subgroup analysis of recent statin trials provide strong support for benefit from intensive cholesterol-lowering therapy in diabetic patients (89,104,105). The decision to employ statin therapy in high-risk, primary prevention goes beyond absolute risk estimates. Both safety and costs of statin therapy must be taken into account. WOSCOPS and AFCAPS/TexCAPS (98,99) revealed a high level of safety of statins over the duration of the trials. This fact helps to justify their use in high-risk patients.
Drug trials were found to be more effective for reducing CHD incidence presumably because of a greater cholesterol lowering. 5%. lO). Effect of cholesterol intervention was not 18 Grundy uniform in all categories. For example, a trend toward a decrease in total mortality appeared to be greater in secondary than in primary prevention trials. Other meta-analyses were subsequently carried out. In 1992, Ravnskov (55) reported a combined analysis of all clinical trials of cholesterol-lowering therapy.
The study is based in the Netherlands, and will last 5 years. Three questions are being addressed: (1) whether hormone replacement therapy is more effective than placebo in preventing vascular events in postmenopausal women with established CHD; (2) whether simvastatin is more effective than placebo in reducing new vascular events; and (3) whether the combination of hormone replacement therapy + simvastatin is more effective than monotherapy . Primary endpoints will be major coronary events and coronary procedures.